Del Carratore Francesco, Hanko Erik Kr, Breitling Rainer, Takano Eriko
Manchester Institute of Biotechnology, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, Manchester M1 7DN, United Kingdom.
Manchester Institute of Biotechnology, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, Manchester M1 7DN, United Kingdom.
Curr Opin Biotechnol. 2022 Oct;77:102762. doi: 10.1016/j.copbio.2022.102762. Epub 2022 Jul 28.
Streptomyces is one of the most relevant genera in biotechnology, and its rich secondary metabolism is responsible for the biosynthesis of a plethora of bioactive compounds, including several clinically relevant drugs. The use of Streptomyces species for the manufacture of natural products has been established for more than half a century; however, the tremendous advances observed in recent years in genetic engineering and molecular biology have revolutionised the optimisation of Streptomyces as cell factories and drastically expanded the biotechnological potential of these bacteria. Here, we illustrate the most exciting advances reported in the past few years, with a particular focus on the approaches significantly improving the biotechnological capacity of Streptomyces to produce clinical drugs and other valuable secondary metabolites.
链霉菌是生物技术领域中最具相关性的属之一，其丰富的次级代谢产物负责多种生物活性化合物的生物合成，包括几种临床相关药物。利用链霉菌属制造天然产物已有半个多世纪的历史；然而，近年来在基因工程和分子生物学方面取得的巨大进展彻底改变了链霉菌作为细胞工厂的优化方式，并极大地扩展了这些细菌的生物技术潜力。在此，我们阐述过去几年报道的最令人振奋的进展，特别关注那些显著提高链霉菌生产临床药物和其他有价值次级代谢产物生物技术能力的方法。
